601607 Stock Overview
Shanghai Pharmaceuticals Holding Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Shanghai Pharmaceuticals Holding Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.07 |
| 52 Week High | CN¥23.20 |
| 52 Week Low | CN¥15.36 |
| Beta | 0.32 |
| 11 Month Change | 6.31% |
| 3 Month Change | 14.35% |
| 1 Year Change | 22.88% |
| 33 Year Change | 19.43% |
| 5 Year Change | 24.90% |
| Change since IPO | 1,238.44% |
Recent News & Updates
Recent updates
Not Many Are Piling Into Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) Just Yet
Sep 30
Shanghai Pharmaceuticals Holding (SHSE:601607) Has Some Way To Go To Become A Multi-Bagger
Aug 09Shanghai Pharmaceuticals Holding's (SHSE:601607) Dividend Is Being Reduced To CN¥0.41
Jul 18Shanghai Pharmaceuticals Holding (SHSE:601607) Has A Somewhat Strained Balance Sheet
Jun 25Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Earnings Are Not Doing Enough For Some Investors
May 21Earnings Miss: Shanghai Pharmaceuticals Holding Co., Ltd Missed EPS By 30% And Analysts Are Revising Their Forecasts
Apr 01Returns At Shanghai Pharmaceuticals Holding (SHSE:601607) Appear To Be Weighed Down
Mar 16We Think Shanghai Pharmaceuticals Holding (SHSE:601607) Can Stay On Top Of Its Debt
Feb 29Shareholder Returns
| 601607 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | 4.6% | -2.9% | -3.4% |
| 1Y | 22.9% | -12.7% | 6.1% |
Return vs Industry: 601607 exceeded the CN Healthcare industry which returned -12.7% over the past year.
Return vs Market: 601607 exceeded the CN Market which returned 6.1% over the past year.
Price Volatility
| 601607 volatility | |
|---|---|
| 601607 Average Weekly Movement | 4.9% |
| Healthcare Industry Average Movement | 8.6% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 601607 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 601607's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 49,234 | Bo Shen | www.sphchina.com |
Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestive system, immune metabolism, motor neuron disease, endocrinology, cardiovascular, psychoneurotic, neoplasm, autoimmunity, systemic anti-infection, mental nerve, anti-tumor, oncology, respiratory system, nervous system, auto-immunity, hypertension, neuromyelitis, diabetes, anticholinesterase, polypeptide hormones uterine tonic, antihistamine, anti-inflammatory, anesthetic, immunomodulatory, antiviral, reflux esophagitis, analgesics, weight management, malignant peritoneal effusion, ulcerative colitis, myasthenia gravis, burn injury, anticoagulant, anti-epileptic, anticonvulsant, Alzheimer’s, and inflammatory bowel diseases.
Shanghai Pharmaceuticals Holding Co., Ltd Fundamentals Summary
| 601607 fundamental statistics | |
|---|---|
| Market cap | CN¥72.37b |
| Earnings (TTM) | CN¥4.03b |
| Revenue (TTM) | CN¥272.42b |
20.3x
P/E Ratio0.3x
P/S RatioIs 601607 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 601607 income statement (TTM) | |
|---|---|
| Revenue | CN¥272.42b |
| Cost of Revenue | CN¥242.27b |
| Gross Profit | CN¥30.14b |
| Other Expenses | CN¥26.12b |
| Earnings | CN¥4.03b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.09 |
| Gross Margin | 11.07% |
| Net Profit Margin | 1.48% |
| Debt/Equity Ratio | 58.2% |
How did 601607 perform over the long term?
See historical performance and comparison